MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414014 | Name: Enecadin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enecadin HCl is a voltage-dependent sodium and calcium channel blocker.

Chemical Structure

Enecadin HCl
Enecadin HCl
CAS#178429-67-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 414014

Name: Enecadin HCl

CAS#: 178429-67-9 (HCl)

Chemical Formula: C21H29ClFN3O

Exact Mass: 0.0000

Molecular Weight: 393.93

Elemental Analysis: C, 64.03; H, 7.42; Cl, 9.00; F, 4.82; N, 10.67; O, 4.06

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
259525-01-4 (free base) 178429-67-9 (HCl)
Synonym
Enecadin hydrochloride; Enecadin HCl; Enecadina; Enecadine; Enecadinum; NS7; NS-7; NS 7; ZK228326; ZK-228326; ZK 228326
IUPAC/Chemical Name
Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-((5-(1-piperidinyl)pentyl)oxy)-, hydrochloride
InChi Key
VLYZLIWXMLUPLD-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H28FN3O.ClH/c1-17-23-20(18-8-10-19(22)11-9-18)16-21(24-17)26-15-7-3-6-14-25-12-4-2-5-13-25;/h8-11,16H,2-7,12-15H2,1H3;1H
SMILES Code
CC1=NC(OCCCCCN2CCCCC2)=CC(C3=CC=C(F)C=C3)=N1.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 393.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Weiss SL, Keele L, Balamuth F, Vendetti N, Ross R, Fitzgerald JC, Gerber JS. Crystalloid Fluid Choice and Clinical Outcomes in Pediatric Sepsis: A Matched Retrospective Cohort Study. J Pediatr. 2017 Mar;182:304-310.e10. doi: 10.1016/j.jpeds.2016.11.075. Epub 2017 Jan 4. PMID: 28063688; PMCID: PMC5525152. 2: Shi E, Kazui T, Jiang X, Washiyama N, Suzuki K, Yamashita K, Terada H. NS-7, a novel Na+/Ca2+ channel blocker, prevents neurologic injury after spinal cord ischemia in rabbits. J Thorac Cardiovasc Surg. 2005 Feb;129(2):364-71. doi: 10.1016/j.jtcvs.2004.05.006. PMID: 15678048. 3: Nonaka K, Tsujioka T, Tougou K, Mukai H. Pharmacokinetics of the new pyrimidine derivative NS-7, a novel Na+/Ca2+ channel blocker. 1st communication: plasma concentrations and excretions after a single intravenous 14C-NS-7 injection to rats, dogs and monkeys. Arzneimittelforschung. 2003;53(9):612-20. doi: 10.1055/s-0031-1297157. PMID: 14558434. 4: Li L, Rutlin M, Abraira VE, Cassidy C, Kus L, Gong S, Jankowski MP, Luo W, Heintz N, Koerber HR, Woodbury CJ, Ginty DD. The functional organization of cutaneous low-threshold mechanosensory neurons. Cell. 2011 Dec 23;147(7):1615-27. doi: 10.1016/j.cell.2011.11.027. PMID: 22196735; PMCID: PMC3262167. 5: Janulaitiene M, Paliulyte V, Grinceviciene S, Zakareviciene J, Vladisauskiene A, Marcinkute A, Pleckaityte M. Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis. BMC Infect Dis. 2017 Jun 5;17(1):394. doi: 10.1186/s12879-017-2501-y. PMID: 28583109; PMCID: PMC5460423. 6: Oka M, Itoh Y, Ukai Y, Kimura K. Blockade by NS-7, a neuroprotective compound, of both L-type and P/Q-type Ca2+ channels involving depolarization- stimulated nitric oxide synthase activity in primary neuronal culture. J Neurochem. 1999 Mar;72(3):1315-22. doi: 10.1046/j.1471-4159.1999.0721315.x. PMID: 10037505. 7: Katsumata T, Muramatsu H, Nakamura H, Nishiyama Y, Aoki Y, Katayama Y. Neuroprotective effect of NS-7, a novel Na+ and Ca2+ channel blocker, in a focal ischemic model in the rat. Brain Res. 2003 Apr 18;969(1-2):168-74. doi: 10.1016/s0006-8993(03)02296-0. PMID: 12676377. 8: Singh R, Ramsuran V, Mitchev N, Niehaus AJ, Han KSS, Osman F, Ngcapu S, Karim SA, Rompalo A, Garrett N, Mlisana K. Assessing a diagnosis tool for bacterial vaginosis. Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1481-1485. doi: 10.1007/s10096-020-03862-3. Epub 2020 Mar 20. PMID: 32193689. 9: Sopala M, Danysz W, Quack G. Neuroprotective effects of NS-7, voltage-gated Na+/Ca2+ channel blocker in a rodent model of transient focal ischaemia. Neurotox Res. 2002 Nov-Dec;4(7-8):655-661. doi: 10.1080/1029842021000045462. PMID: 12709303. 10: Haptonstall KP, Choroomi Y, Moheimani R, Nguyen K, Tran E, Lakhani K, Ruedisueli I, Gornbein J, Middlekauff HR. Differential effects of tobacco cigarettes and electronic cigarettes on endothelial function in healthy young people. Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H547-H556. doi: 10.1152/ajpheart.00307.2020. Epub 2020 Jul 31. PMID: 32734819; PMCID: PMC7509270.

View History

Endosidin8.1

Endosidin8.1

ACC2-IN-2e

ACC2-IN-2e

FG-8119

FG-8119

Boronophenylalanine HCl

Boronophenylalanine HCl